Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody C(44)Mab-108 for Immunohistochemistry

开发一种新型抗CD44变体4单克隆抗体C(44)Mab-108用于免疫组织化学

阅读:2

Abstract

CD44 has been known as a marker of tumor-initiating cells, and plays pro-tumorigenic functions in many cancers. The splicing variants play critical roles in the malignant progression of cancers by promoting stemness, cancer cell invasion or metastasis, and resistance to chemo- and radiotherapy. To understand each CD44 variant (CD44v) function is essential to know the property of cancers and the establishment of the therapy. However, the function of the variant 4-encoded region has not been elucidated. Therefore, specific monoclonal antibodies (mAbs) against variant 4 are indispensable for basic research, tumor diagnosis, and therapy. In this study, we established anti-CD44 variant 4 (CD44v4) mAbs by immunizing mice with a peptide containing the variant 4-encoded region. We next performed flow cytometry, western blotting, and immunohistochemistry to characterize them. One of the established clones (C(44)Mab-108; IgG(1), kappa) reacted with CD44v3-10-overexpressed Chinese hamster ovary-K1 cells (CHO/CD44v3-10). The K(D) of C(44)Mab-108 for CHO/CD44 v3-10 was 3.4 × 10(-7) M. In western blot analysis, C(44)Mab-108 detected CD44v3-10 in the lysate of CHO/CD44v3-10 cells. Furthermore, C(44)Mab-108 stained formalin-fixed paraffin-embedded (FFPE) oral squamous carcinoma tissues in immunohistochemistry. These results indicated that C(44)Mab-108 is useful to detect CD44v4 in immunohistochemistry using FFPE tissues.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。